Tango Biosciences publishes work on SARS-CoV-2 virus

Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and the S1 spike subunit, with affinities ranging from 3 to 14 nM as measured by bio-layer interferometry. All four monobodies successfully bound the RBD after overexpression in Chinese hamster ovary (CHO) cells as fusions to the Fc domain of human IgG1. The paper was published February 5, 2021 in the peer-reviewed journal, New Biotechnology, and can be found below.